NCT04439110 2025-11-21Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)National Cancer Institute (NCI)Phase 2 Active not recruiting38 enrolled 10 charts